U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294534) titled 'A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer' on Dec. 08.
Brief Summary: The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
Study Start Date: Jan. 27, 2026
Study Type: INTERVENTIONAL
Condition:
HER2 + Breast Cancer
Intervention:
DRUG: HLX87+HX22
HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 i...